Click here for United Kingdom
prescribing information
Click here for Republic of Ireland
prescribing information
Adverse Event Reporting details can be found at the bottom of this page
Doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).1
References
1. Doptelet EMC Summary of Product Characteristics. Available at: www.medicines.org.uk/emc/product/11837/smpc#gref Last accessed: April 2025.
Doptelet is a registered trademark of AkaRx, Inc., a Sobi company. Sobi is a trademark of Swedish Orphan Biovitrum AB (publ) © 2025 Sobi, Inc. – All rights reserved.
Adverse events should be reported. Reporting forms and information can be found at
www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App
Store (for United Kingdom) and www.hpra.ie (for Republic of Ireland). Adverse events should also be reported to Swedish Orphan Biovitrum Ltd at [email protected] or Telephone +44 (0) 800 111 4754